Company / Cash & Equivalents
Gilead Sciences Cash & Equivalents History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.3B
FY2021
5-year range
$5.3B / $5.3B
FY2017-FY2021
Trend
-11.0%
vs FY2020
Sector context
#6 of 207
Health Care
What the data says
Among 207 Health Care companies, Gilead Sciences is in the top 3% for cash & equivalents. Cash & Equivalents has fluctuated over the past 6 years, ranging from $5.3B in FY2021 to $12.9B in FY2017.
Based on SEC 10-K filings.
$5.3B in FY2021 with a 5-year CAGR of -11.8%. Top quartile in the Health Care sector.
Declined from $11.6B to $5.3B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.1%
- 5-Year CAGR
- -11.8%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 207This company $5.3B Sector average $669.5M
▼
+697.3% above sector average
Key checks
Key Insights
- 5-year CAGR of -11.8%, indicating a declining trend.
- In FY2021, cash & equivalents decreased 11.0% year-over-year.
- Ranks #6 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2017.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $5.3B | -11.0% |
| FY2020 | $6.0B | -48.4% |
| FY2019 | $11.6B | +53.3% |
| FY2018 | $7.6B | -41.0% |
| FY2017 | $12.9B | +28.2% |
| FY2016 | $10.0B | -22.0% |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026